It has been just over two decades since the first nanoparticle-based therapy was FDA approved for the treatment of cancer.
In that time, the field has grown and matured significantly, attracting the interest of an increasing number of researchers across multiple disciplines, said Piotr Grodzinski, PhD, the Chief of Nanodelivery Systems and Devices Branch at the Cancer Imaging Program of the National Cancer Institute (NCI).
“I have this plot that shows the number of publications per year within nanotechnology in medicine and it was close to zero in year 2000,” said Grodzinski in an interview with R&D Magazine. “Today there are about 20,000 papers written on this topic each year. A lot of researchers are starting to work in this area and we (the NCI) are receiving large number of grant applications concerning the use of nanomaterials and nano-devices in novel cancer interventions. In last three years there has been two FDA approvals of new nanoparticle-based treatments and a multitude of clinical trials… Continue reading.